210 related articles for article (PubMed ID: 33603167)
41. Promoter specificity and stability control of the p53-related protein p73.
Lee CW; La Thangue NB
Oncogene; 1999 Jul; 18(29):4171-81. PubMed ID: 10435630
[TBL] [Abstract][Full Text] [Related]
42. Identification of DeltaN isoform and polyadenylation site choice variants in molluscan p63/p73-like homologues.
Muttray AF; Cox RL; Reinisch CL; Baldwin SA
Mar Biotechnol (NY); 2007; 9(2):217-30. PubMed ID: 17242983
[TBL] [Abstract][Full Text] [Related]
43. Role of the newer p53 family proteins in malignancy.
Irwin MS; Kaelin WG
Apoptosis; 2001; 6(1-2):17-29. PubMed ID: 11321038
[TBL] [Abstract][Full Text] [Related]
44. Molecular characterization of TP53 gene in human populations exposed to low-dose ionizing radiation.
Brasil-Costa I; Alencar DO; Raiol-Moraes M; Pessoa IA; Brito AW; Jati SR; Santos SE; Burbano RM; Ribeiro-dos-Santos AK
Biomed Res Int; 2013; 2013():303486. PubMed ID: 23586029
[TBL] [Abstract][Full Text] [Related]
45. Circular RNA CDR1as disrupts the p53/MDM2 complex to inhibit Gliomagenesis.
Lou J; Hao Y; Lin K; Lyu Y; Chen M; Wang H; Zou D; Jiang X; Wang R; Jin D; Lam EW; Shao S; Liu Q; Yan J; Wang X; Chen P; Zhang B; Jin B
Mol Cancer; 2020 Sep; 19(1):138. PubMed ID: 32894144
[TBL] [Abstract][Full Text] [Related]
46. Differential chromatin accessibility landscape of gain-of-function mutant p53 tumours.
Dhaka B; Sabarinathan R
BMC Cancer; 2021 Jun; 21(1):669. PubMed ID: 34090364
[TBL] [Abstract][Full Text] [Related]
47. Age-dependent copy number variations of TP53 tumour suppressor gene associated with altered phosphorylation status of p53 protein in sporadic schwannomas.
Chen H; Huang H; Zhao J; Wang Z; Chang M; Xue L; Zhu W; Chai Y; Li G; Wang Z; Wu H
J Neurooncol; 2019 Jul; 143(3):369-379. PubMed ID: 31049827
[TBL] [Abstract][Full Text] [Related]
48. Clinical and Functional Significance of TP53 Exon 4-Intron 4 Splice Junction Variants.
Pinto EM; Maxwell KN; Halalsheh H; Phillips A; Powers J; MacFarland S; Walsh MF; Breen K; Formiga MN; Kriwacki R; Nichols KE; Mostafavi R; Wang J; Clay MR; Rodriguez-Galindo C; Ribeiro RC; Zambetti GP
Mol Cancer Res; 2022 Feb; 20(2):207-216. PubMed ID: 34675114
[TBL] [Abstract][Full Text] [Related]
49. Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma.
Voropaeva EN; Pospelova TI; Voevoda MI; Maksimov VN; Orlov YL; Seregina OB
BMC Med Genomics; 2019 Mar; 12(Suppl 2):35. PubMed ID: 30871527
[TBL] [Abstract][Full Text] [Related]
50. BRCA2 and TP53 collaborate in tumorigenesis in zebrafish.
Shive HR; West RR; Embree LJ; Golden CD; Hickstein DD
PLoS One; 2014; 9(1):e87177. PubMed ID: 24489863
[TBL] [Abstract][Full Text] [Related]
51. Expression of p53 family genes in urinary bladder cancer: correlation with disease aggressiveness and recurrence.
Papadogianni D; Soulitzis N; Delakas D; Spandidos DA
Tumour Biol; 2014 Mar; 35(3):2481-9. PubMed ID: 24213852
[TBL] [Abstract][Full Text] [Related]
52. Overlapping region of p53/wrap53 transcripts: mutational analysis and sequence similarity with microRNA-4732-5p.
Pouladi N; Kouhsari SM; Feizi MH; Gavgani RR; Azarfam P
Asian Pac J Cancer Prev; 2013; 14(6):3503-7. PubMed ID: 23886136
[TBL] [Abstract][Full Text] [Related]
53.
Gadea G; Arsic N; Fernandes K; Diot A; Joruiz SM; Abdallah S; Meuray V; Vinot S; Anguille C; Remenyi J; Khoury MP; Quinlan PR; Purdie CA; Jordan LB; Fuller-Pace FV; de Toledo M; Cren M; Thompson AM; Bourdon JC; Roux P
Elife; 2016 Sep; 5():. PubMed ID: 27630122
[No Abstract] [Full Text] [Related]
54. Patterns of structural variants within TP53 introns and relocation of the TP53 promoter: a commentary
Beird HC; Lin D; Lazar AJ; Futreal PA
J Pathol; 2024 Jun; 263(2):131-134. PubMed ID: 38482738
[TBL] [Abstract][Full Text] [Related]
55. Discovery of TP53 splice variants in two novel papillary urothelial cancer cell lines.
Koch A; Hatina J; Rieder H; Seifert HH; Huckenbeck W; Jankowiak F; Florl AR; Stoehr R; Schulz WA
Cell Oncol (Dordr); 2012 Aug; 35(4):243-57. PubMed ID: 22669776
[TBL] [Abstract][Full Text] [Related]
56. Elevation of the TP53 isoform Δ133p53β in glioblastomas: an alternative to mutant p53 in promoting tumor development.
Kazantseva M; Eiholzer RA; Mehta S; Taha A; Bowie S; Roth I; Zhou J; Joruiz SM; Royds JA; Hung NA; Slatter TL; Braithwaite AW
J Pathol; 2018 Sep; 246(1):77-88. PubMed ID: 29888503
[TBL] [Abstract][Full Text] [Related]
57. The C terminus of p53 family proteins is a cell fate determinant.
Harms KL; Chen X
Mol Cell Biol; 2005 Mar; 25(5):2014-30. PubMed ID: 15713654
[TBL] [Abstract][Full Text] [Related]
58. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
Yeudall WA; Vaughan CA; Miyazaki H; Ramamoorthy M; Choi MY; Chapman CG; Wang H; Black E; Bulysheva AA; Deb SP; Windle B; Deb S
Carcinogenesis; 2012 Feb; 33(2):442-51. PubMed ID: 22114072
[TBL] [Abstract][Full Text] [Related]
59. p53 regulates the transcription of its Delta133p53 isoform through specific response elements contained within the TP53 P2 internal promoter.
Marcel V; Vijayakumar V; Fernández-Cuesta L; Hafsi H; Sagne C; Hautefeuille A; Olivier M; Hainaut P
Oncogene; 2010 May; 29(18):2691-700. PubMed ID: 20190805
[TBL] [Abstract][Full Text] [Related]
60. Quantitative TP73 transcript analysis in hepatocellular carcinomas.
Stiewe T; Tuve S; Peter M; Tannapfel A; Elmaagacli AH; Pützer BM
Clin Cancer Res; 2004 Jan; 10(2):626-33. PubMed ID: 14760085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
